Phase 1 clinical trials have been completed in multiple myeloma patients with the t(4; 14) translocation causing overexpression of FGFR3 (NCT01122875) and advanced solid tumours (NCT01363024). This evidence concerns the gene FGFR3 and AL amyloidosis.